AKBA Q3 2022 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M-0.1% YoY

Gross Profit

$10M21.4% margin

Operating Income

-$50M-103.5% margin

Net Income

-$54M-111.0% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-61.4%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$34M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$436M

Total Liabilities

$422M

Stockholders' Equity

$14M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$49M	-0.1%
Gross Profit	$10M	$33M	-68.2%
Operating Income	-$50M	-$55M	+8.2%
Net Income	-$54M	-$60M	+9.1%

Revenue Segments

Product

$42M86%

License Collaboration And Other Revenue

$7M14%